



Biotechnology and Pharmaceuticals

in the Capital Region Berlin-Brandenburg



Takeda's Oranienburg location – center of excellence for fixed forms in the worldwide production network



The CoLaborator from Bayer provides the perfect environment for young companies in the life sciences.

Biotech

- Analyticon Discovery
- Biochrom
- BIOTECON Diagnostics
- Co.don
- Epigenomics
- Glycotope
- Ifp Institut für Produktqualität
- In.vent DIAGNOSTICA
- InVivo Biotech Services
- JPT Peptide Technologies
- KNAUER
- Wissenschaftliche Geräte
- LGC
- metanomics
- MOLOGEN
- NOXXON Pharma
- Organobalance
- ProBioGen
- Seramun Diagnostica
- SGS INSTITUT
- FRESENIUS Berlin
- SIFIN
- Silence Therapeutics
- Thermo Fisher Scientific – B·R·A·H·M·S
- TIB MOLBIOL

For a complete overview of all the companies, see our Life Sciences Report.

Leading European location for biotechnology

Biotechnology is an engine of innovation in the Berlin-Brandenburg region. The sector is recording steady growth and a high rate of company start-ups. This positive trend is based on the region's excellent research landscape and technology parks specialized in biotechnology. They provide optimal conditions for start-ups and large, research-intensive companies alike. Of the more than 240 biotechnology companies with approx. 5,000 employees here, 80% focus on biomedicine. They develop innovative therapeutic and diagnostic procedures for the treatment of cancer, cardiovascular diseases and diabetes, and benefit from the region's excellent science and top infrastructure for clinical studies. Berlin-Brandenburg possesses expertise in genome and proteome research, diagnostics, regenerative medicine, RNA technologies and glyco-engineering technology.



region into a true magnet for healthcare investments in Europe.«

Stefan Oelrich
Senior Vice President
Head Global Diabetes Franchise
Sanofi-Aventis Deutschland GmbH

»The Berlin-Brandenburg metropolitan area is a unique place inside the German healthcare sector. Nowhere else in Germany will you find a comparable concentration of world class science, hospitals and industry. This cross-functional cluster turns the German capital



Dr. Clane Pereira
General Manager
Vaxxilon Deutschland GmbH

»The technology for our innovative vaccines originated at the Max Planck Institute of Colloids and Interfaces which is located in the greater Berlin area. So it was natural to locate Vaxxilon in the region. We received excellent support from the Adlershof Technology Park to establish our offices and laboratories.«

Pharmaceuticals location with a rich history and modern dynamics

The sustained success of pharmaceutical companies in Berlin and Brandenburg is based on innovative products and a venerable tradition reaching back to the 19th century. The sector benefits from an excellent scientific environment and clinical research landscape, and its proximity to the health care system decision makers. This applies to global players such as Bayer, Pfizer, Sanofi, Takeda and Berlin-Chemie (Menarini) and to more than 20 additional medium-sized pharmaceuticals companies with a total of 10,000 employees. Many international corporations such as Daiichi Sankyo and Astra Zeneca also have representative offices in Berlin.

Bayer Pharma can look back at a long history in Berlin. Today, the company is one of the world's leading speciality pharmaceuticals companies. More than 1,000 Sanofi employees manage the company's marketing and sales activities in Berlin. In 2011, Takeda Pharma took over the Nycomed Group and only one year later, moved its sales headquarters to Berlin. Takeda is currently investing €100 million to expand its production facilities



Production of biomarkers at B.R.A.H.M.S GmbH in Hennigsdorf

- Leading German biotechnology location with over 240 companies in the sector
- Pharmaceuticals location with a rich history
- Outstanding conditions for clinical research
- Excellent access to skilled specialists due to the many degree, training and continuing education programs
- Outstanding science landscape featuring Charité – Universitätsmedizin Berlin and many other university and non-university research institutions (Max Planck, Fraunhofer and Leibniz Institutes and the Helmholtz Centers)
- Political center and seat of the vfa, BPI and BIO Deutschland sector associations, as well as health insurance companies and patient organisations
- Tight network among science and business through interdisciplinary partnerships in the areas of biotechnology, diagnostics, pharmaceuticals, medical technology, photonics and ICT

in Oranienburg. Pharmaceuticals giant Pfizer is also expanding its activities in the capital region, establishing other business units to supplement its German headquarters here. For example, the company manages its oncology business unit for Europe from Berlin. In 2014 Riemser Pharma reinforced its sales activities with an operations-related unit in Berlin. In 2015 Boehringer Ingelheim opened a representative office in the capital. Berlin-Chemie is investing €80 million to expand its production facilities in the south of Berlin. Dr. Kade, which has been growing in the capital region for over 25 years, has taken over Takeda's OTC business. And the fact that Klosterfrau Berlin invested in a new production hall in 2013 also shows that Berlin has developed into an important production location in recent years.

Clinical research

The close connection between research, development and the clinics here is most obviously demonstrated by the region's successful, well-established translational research and the wide range of opportunities available for implementing clinical studies. With its large, extremely diverse patient collective, Berlin-



»Since it was founded as a spin-off from the Freie Universität, MOLOGEN has resided in Berlin. We value the excellent research and clinic landscape, and benefit from the network of research institutions and industry experts. As pioneers in the field of immunotherapy, we are developing drug candidates to combat cancer and severe infectious diseases.«

Dr. Mariola Söhngen
CEO
MOLOGEN AG



»The Berlin-Brandenburg region is a leading location for healthcare in Germany. The proximity to science and research, and also to health policy actors, make it the ideal location for our sales center and one of our production facilities. In producing and distributing mostly speciality drugs, we employ over 1,000 workers and trainees in Berlin and Brandenburg.«

Günter Kloucek
CEO
Takeda Pharma Vertrieb GmbH & Co. KG

Brandenburg facilitates all kinds of clinical research projects. Charité – Universitätsmedizin Berlin and CROs such as Parexel – active with over 1,000 employees in Berlin – and other smaller providers that supervise studies of all types all play outstanding roles in this area.

Optimal conditions for start-ups

The nine biotechnology parks in the region provide optimal conditions for young, growing companies. Over 50% of the biotechnology companies use the programs of the state-owned or privately operated parks, which offer a variety of contextual focal areas. In addition to the availability of laboratory space and an extensive technical infrastructure, they benefit from the close contact and intense exchange with the research institutions and multi-faceted service providers that are also located in the parks.

When it comes to early stage financing, the states' own business development banks have investment companies whose technology funds play an important role. Projects such as Bayer's CoLaborator are evidence of the major pharmaceuticals corporations' involvement.

Pharma

Aenova/
Haupt Pharma Berlin
Aristo Pharma
Bausch + Lomb
Bayer Pharma
Berlin-Chemie (Menarini Group)
DR. KADE
Pharmazeutische Fabrik
Klosterfrau Berlin
Merz Pharmaceuticals
Next Pharma
Pfizer
Riemser Pharma
Sanofi
Shire
Takeda Pharma
Teva

Networks

BioResponse Network
Center for Molecular
Diagnostics and
Bioanalytics (ZMDB)
DiagnostikNet-BB
glyconet Berlin
Brandenburg

Biotech-Parks

berlinbiotechpark
Biotech Campus Potsdam
Biotechnologiepark
Luckenwalde
Campus Berlin-Buch
co:bios Technologiezentrum
Hennigsdorf
GO:IN Golm Innovations-
zentrum, Potsdam
Science and Technology
Park Adlershof
Techno Terrain Teltow
Wuhlheide Innovation Park



HealthCapital
BERLIN BRANDENBURG

Our aim: your success!

Berlin and Brandenburg support the biotechnology and pharma focal area with an economic policy developed across state borders in the Healthcare industries cluster. The cluster is managed under the aegis of Berlin Partner for Business and Technology and the Brandenburg Economic Development Corporation.

Our aim is to provide comprehensive support to companies and scientific institutions interested in inward investment or further development in the capital region.

We are ready to assist you with:

- **Company start-up**
- **Location search**
- **Funding and financing**
- **Technology transfer and R&D partnerships**
- **Cooperating in networks**
- **Employee recruiting, programs designed to retain skilled specialists and qualification**
- **International market development**

Reach out and contact us!

www.healthcapital.de

PHOTOS: Cover: YAZ-Flex production in Berlin, Bayer. Inside: Takeda/Sebastian Bolesch, Bayer, B•R•A•H•M•S
DESIGN: Büro Watkinson, Berlin. **PRINT:** LASERLINE, Berlin

© October 2016



Berlin Partner für Wirtschaft und Technologie GmbH

Fasanenstr. 85
10623 Berlin
www.berlin-partner.de
Twitter: @BerlinPartner

Contact:

Carolin Clement
T +49 30 46302 430
carolin.clement@berlin-partner.de

Brandenburg Invest | WFBB

Wirtschaftsförderung Land Brandenburg GmbH

Babelsberger Straße 21
14473 Potsdam
www.wfbb.de

Contact:

Stefan Bauer
T +49 331 20029 253
stefan.bauer@wfbb.de



EUROPEAN UNION

European Regional Development Fund

Publisher: Berlin Partner for Business and Technology in cooperation with the Brandenburg Economic Development Corporation. Funded by the State of Berlin and the State of Brandenburg as well as the Investitionsbank Berlin, cofunded by the European Union – European Regional Development Fund.